215
Views
45
CrossRef citations to date
0
Altmetric
Review

Ras/Raf signalling and emerging pharmacotherapeutic targets

Pages 709-718 | Published online: 25 Feb 2005
 

Abstract

The Ras-Raf-MEK-ERK pathway is a ubiquitously expressed signalling module that regulates the proliferation, differentiation and survival of cells. This pathway features several oncogenes and is deregulated in ~ 30% of all human cancers. Thus, it has emerged as a prime target for antitumour therapy. Drugs targeting Ras, Raf or MEK are currently in clinical trials. They comprise vaccines, isoprenylation inhibitors, antisense compounds and kinase inhibitors. Most are remarkably well tolerated and some show promising efficacy. However, it is not clear which components of this pathway should be targeted and how maximum efficacy can be achieved. This paper reviews the current efforts with an emphasis on new mechanistic and conceptual approaches.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.